Release of EPEMED 2014 Patient Access Study
This work serves as an evidence-based learning platform to provide vital insight and informed national and European recommendations to change and improve patient access to new pharmaceutical drug and/or the associated companion diagnostic. The report study was already presented to European and national institutions in direct meetings.
Objectives and Methodology
The objectives of the study were to
Conduct an environmental analysis of patient access pathways to pharmaceutical drug-diagnostic companion products from a patient’s perspective in the 5 most populated EU countries (Germany, England, France, Italy and Spain).
Identify key factors impeding and facilitating patient access
Develop country-specific and Europe-wide recommendations for improved patient access
The Charité analysis was overseen by an EPEMED Steering Committee incorporating Key Opinion Leaders drawn from EPEMED’s membership and collaborating partners[R1] . The design drew on both secondary and primary research conducted by La Charité, including a review of relevant publications and 30 exploratory interviews with EU expert stakeholders.
The resulting study is a 50+ page analysis comprising a detailed overview and a series of policy recommendations.